secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001214659-24-009345
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro furnishes updated investor presentation for May 2024; no specific new disclosures provided
--------------------------------------------------------------------------------

- Filed under Item 7.01 as a Regulation FD disclosure; presentation furnished as Exhibit 99.1.
- Presentation covers therapeutic drugs for Alzheimer's and other neurodegenerative/psychiatric disorders.
- No financial data, clinical trial results, or milestones explicitly stated in the filing's exhibit text.
- Company uses the presentation in meetings with investors, stockholders, and analysts.
- Filing emphasizes forward-looking statements and risks; no material operational changes announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924009345/0001214659-24-009345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924009345/g5152428k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-24-009345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer